Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-05-25
1996-10-01
Elliott, George C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 530415, 530417, 530381, 530829, 435 2, A61K 3839, C07K 114, C07K 1478, C08B 514
Patent
active
055611141
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a selective adsorbent for cellular fibronectin (cFN) and a technology for fractional purification of fibronectin (FN), particularly a method for fractionating an FN matter containing both plasma fibronectin (pFN) and cFN into pFN and cFN and a method of hemocatharisis comprising eliminating cFN from blood by the above method.
BACKGROUND ART
Fibronectin (FN) was first reported by Morrison et al. [Morrison, P. R. et al., J. Am. Chem. Soc., 70, 3103 (1948)] as one of plasma proteins in 1948. Being a multifunctional protein broadly distributed in various tissues and body fluids, this substance is known to be involved, as a cell adhesion factor, in a large variety of biological events such as the migration, differentiation, proliferation and canceration of cells [Sekiguchi, K.: Cell Engineering, 4 (6), 485-497 (1985)].
Meanwhile, FN as it is synthesized in the liver and occurring in the blood is known as plasma FN (pFN), and FN as it is detected on the tissue and cell surfaces is called cellular FN (cFN) [Sekiguchi et al., J. Biol. Chem., 260 (8) 5105-5114 (1985)]. It has been shown that these species of FN are subject to molecular diversity due to alternative splicing of the early gene transcription product. As the regions subject to such alternative splicing, there are three regions called EDA, EDB and IIIcs, and it is believed that a large number of molecular species occur according to varied combinations of expression of these regions. In pFN, the above-mentioned EDA and EDB regions have not been appreciably expressed. On the other hand, cFN is an FN with a high degree of expression of said EDA region. Peters J. H. et al. conjugated a peptide having 29 amino acids with keyhole limpet hemocyanin (KLH) to prepare an immunogen, constructed an anti-cFN polyclonal antibody specifically reactive to cFN having the EDA region, and using the antibody, demonstrated that the normal human blood contains traces of cFN and that the blood cFN level is markedly elevated in patients with collagen disease accompanied by vasculitis [Am. Rev. Respir. Dis., 138, 167-174 (1988); J. Lab. Clin. Med., 113 (5), 586-597 (1989)]. According to the above report of Peters et al., the physiological implications of increased blood cFN in patients with collagen disease accompanied by vasculitis are not definitely known but a correlation between the stage or severity of disease and the blood concentration of cFN is suggested.
The investigation made by the inventors of the present invention revealed that whereas the plasma concentration of cFN in healthy humans is 1 to 2 .mu.g/ml, it is as high as 10 and odd .mu.g/ml in patients with various diseases. On the other hand, pFN is invariably within the normal range of 270 to 400 .mu.g/ml, irrespective of subjects.
Therefore, it is a subject of intriguing interest to investigate how the course of disease is modified by selective elimination of cFN from the blood of patients with collagen disease presenting with abnormal elevations of cFN. The recent study by the inventors of the present invention uncovered that when the plasma of a patient with rheumatoid arthritis is subjected to cryofiltration, cFN is partially removed from the plasma, resulting in relief of the symptoms. However, the cryofiltration procedure is disadvantageous in that it involves discarding of the useful plasma protein in large quantities and is not capable of selective elimination of cFN.
The inventors of the present invention previously developed a method for separating and eliminating cFN selectively from the patient's blood and a selective cFN adsorbent for the elimination thereof and filed a patent application (PCT/JP92/00359). It was, however, subsequently discovered that, occurring as granules or gels, the cFN adsorbent disclosed in the above application has the drawback that it incurs a high production cost, must be maintained in wet condition and, in packing it into an adsorption module column for extra-corporeal circulation, must be handled as floated on water.
In v
REFERENCES:
patent: 3673110 (1972-06-01), Edwards
patent: 3804092 (1974-04-01), Tune
patent: 4389523 (1983-06-01), Okajima et al.
patent: 4744899 (1988-05-01), Tani et al.
patent: 5234823 (1994-06-01), Asakawa et al.
Sekiguchi et al., "Differences In Domain Structure Between Human Fibronectins Isolated from Plasma & from Culture Supernatants of Normal & Transformed Fibroblasts" J Biol Chem 260(8) 5105-5114 1985.
Inoue Fujio
Kamogawa Hiroshi
Komai Takashi
Miyashita Keiichi
Sakashita Eiji
Degen Nancy J.
Elliott George C.
Nissinbo Industries Inc.
Otsuka Pharmaceutical Factory Inc.
LandOfFree
Adsorbent for cellular fibronectin, a method for fractional puri does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adsorbent for cellular fibronectin, a method for fractional puri, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adsorbent for cellular fibronectin, a method for fractional puri will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1502057